Efficacy of Ginkgolide B in the prophylaxis of migraine with aura.
Total years in practice: 3
May 01, 2009
Giovanni D'Andrea, Gennaro Bussone, Gianni Allais, Marco Aguggia, Florindo D'Onofrio, Maurizio Maggio, Franca Moschiano, Maria Gabriella Saracco, Maria Grazia Terzi, Vittorio Petretta, Chiara Benedetto
Neurol Sci. 2009 May;30 Suppl 1:S121-4. PMID: 19415441
Herbal Therapy, Holistic Medicine
In a multicentric, open, preliminary trial, we evaluated the use of ginkgolide B, a herbal constituent extract from Ginkgo biloba tree leaves, in the prophylactic treatment of migraine with aura (MA). Fifty women suffering from migraine with typical aura, or migraine aura without headache, diagnosed according to International Headache Society criteria, entered a six-month study. They underwent a two month run-in period free of prophylactic drugs, followed by a four month treatment period (subdivided into two bimesters, TI and TII) with a combination of 60 mg ginkgo biloba terpenes phytosome, 11 mg coenzyme Q 10, and 8.7 mg vitamin B2 (Migrasoll), administered twice daily. A detailed diary reporting neurological symptoms, duration, and frequency of MA was compiled by patients throughout the trial. The number of MA significantly decreased during treatment (from 3.7 +/- 2.2 in the run-in period, to 2.0 +/- 1.9 during TI and to 1.2 +/- 1.6 during TII; Anova for repeated measures: P
Get more information via email